Opinions
Robert McWhirter
Microbix Biosystems
MBX-T
TOP PICK
May 17, 2019
A very thinly traded stock. They are involved in biomedical testing. They reported earnings up 40%. He sees great opportunity to increase capacity. He expects a 13 times PE going forward -- very reasonable. ROE 15%. His third largest holding. Yield 0% (Analysts’ price target is $0.71)
$0.350
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
WEAK BUY
Been around for a long time. Has a broad range of technologies. Have recently signed licensed for Virusmax, which can double the yield of virus production for vaccinations. Bull semen-sexing technology. Have some very interesting technologies. Watching it very closely. Like the company.
biotechnology
pharmaceutical
STRONG BUY
PAST TOP PICK
TOP PICK
They're involved in Covid testing. Sales should more than double by Sept. 2021 year end to $25 million with a further 32% growth in sales of 2022 to $34 million. He expects Covid testing will continue to be common for employees and travellers. This stock could double from current levels. Other analysts target even higher, but this is a speculative stock. (Analysts’ price target is $0.80)
biotechnology
pharmaceutical
BUY
Very positive on the stock price, the company, and the partnerships they're announcing. Technicals indicate the stock may head toward 90 cents, but he says higher. Just won a contract from the Ontario government. Covid testing isn't going away. Sales should triple in the next 12 months.
biotechnology
pharmaceutical
Advertising